At the Malaysian Thoracic Society Annual Scientific Congress 2017 held recently in Kuala Lumpur, Associate Professor Pang spoke on the importance of influenza vaccination in patients with chronic respiratory diseases and lung cancer, highlighting the benefit of quadrivalent influenza vaccines (QIVs) in providing a wider spectrum of protection against influenza types A and B.
Allergic rhinitis (AR) is a common global health problem that poses a significant impact on the quality of life and productivity of affected patients. At the Ear, Nose and Throat (ENT) Summit 2017 held recently at Hilton Sentral, Kuala Lumpur, Malaysia, Associate Professor Marysia P Tiongco-Recto was invited by A. Menarini to deliver a lecture on the potential of modern second-generation antihistamines, particularly bilastine (Bilaxten®) in the management of AR.
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
The common cold is one of the most widespread illness and is a leading cause of visits to the doctor and absenteeism from school and work. While many may see it as merely a harmless inconvenience, the significant repercussions it brings, especially among children cannot be denied. MIMS JPOG recently spoke to Associate Professor Datin Dr Asmiati Abd Hamid to gain her perspectives on the role of zinc and vitamin C in treating paediatric common cold to reduce morbidity and economic losses attributed to the condition.
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 20170514091000
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Idiopathic pulmonary fibrosis (IPF) is a disease marked by scarring and hardening of lung tissues. As a result, the lungs are unable to take in oxygen normally, which leads to lack of oxygen in the bloodstream, causing functional impairment and disability.1 Respiratory medicine experts, Professor Dr Paul W. Noble and Professor Dr Liam Chong Kin recently spoke to MIMS Doctor on IPF diagnosis and treatment. Here are the highlights from the interview.
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
The main goal of the National Strategic Plan (NSP) for TB Control (2016 to 2020) is to reduce tuberculosis (TB) burden by ensuring universal access to timely and quality diagnosis and treatment of all types of TB, and preventing the development of drug resistant TB, says an expert.